Research programme: antiviral antibody therapeutics - Stadius Biopharma
Latest Information Update: 25 Jan 2022
At a glance
- Originator Stadius Biopharma
- Class Antibodies; Antivirals
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Viral infections
Most Recent Events
- 14 Jan 2022 Early research in Viral infections (Prevention) in USA (Parenteral) (Stadius Biopharma pipeline, January 2022)
- 14 Jan 2022 Early research in Viral infections in USA (Parenteral) (Stadius Biopharma pipeline, January 2022)